Abstract: When the International Agency for Research on Cancer (IARC) classified shift‐work that involves circadian disruption as probably carcinogenic to humans in 2007, this was the prelude to extensive experimental and epidemiological research in coming years. Indeed, with some 20% of people worldwide being engaged in some type of work at unusual times, including the night, it is a must to investigate, and to clarify as soon as possible, the biologically plausible links via circadian disruption with epidemic cancers such as of the breast or prostate. Surprisingly, neither the IARC information available so far nor the general literature provides a clear definition of what the critical component in the postulated chain of causation, namely circadian disruption, is. Here we offer our definition of chronodisruption (CD), a concept which we proposed in 2003 and which we operationalized recently in research which addressed the putative links between shift‐work, time‐zone‐travel and human cancers independently of the IARC and led to similar causal interpretations. As a basis for further research in this area with possible high relevance for public health, we: (i) elaborate our definition of CD, with melatonin being a key biological intermediary, by putting critical disruptions, and the resulting disorder, of circadian clocks, biological rhythms and circadian organization into thematic and historical context with Colin Pittendrigh’s insights almost half a century ago; (ii) provide material on ‘what are chronodisruptors?’ and (iii) pose a key question which needs to be answered by and for experimental and epidemiological CD research. We hope that defining CD can contribute to studies which may help to find clues to a background incidence of epidemic internal cancers for which – so far in many cases – we lack causal explanations.
Mortality effects of exposure to air pollution and other environmental hazards are often described by the estimated number of “premature” or “attributable” deaths and the economic value of a reduction in exposure as the product of an estimate of “statistical lives saved” and a “value per statistical life.” These terms can be misleading because the number of deaths advanced by exposure cannot be determined from mortality data alone, whether from epidemiology or randomized trials (it is not statistically identified). The fraction of deaths “attributed” to exposure is conventionally derived as the hazard fraction (R – 1)/R, where R is the relative risk of mortality between high and low exposure levels. The fraction of deaths advanced by exposure (the “etiologic” fraction) can be substantially larger or smaller: it can be as large as one and as small as 1/e (≈0.37) times the hazard fraction (if the association is causal and zero otherwise). Recent literature reveals misunderstanding about these concepts. Total life years lost in a population due to exposure can be estimated but cannot be disaggregated by age or cause of death. Economic valuation of a change in exposure‐related mortality risk to a population is not affected by inability to know the fraction of deaths that are etiologic. When individuals facing larger or smaller changes in mortality risk cannot be identified, the mean change in population hazard is sufficient for valuation; otherwise, the economic value can depend on the distribution of risk reductions.